Document is current
Any future updates will be listed below
-
Authors
Sun, Weina https://orcid.org/0000-0002-2435-5047
Liu, Yonghong
Amanat, Fatima https://orcid.org/0000-0002-8029-8227
González-Domínguez, Irene https://orcid.org/0000-0002-7920-5505
McCroskery, Stephen
Slamanig, Stefan https://orcid.org/0000-0003-3694-6597
Coughlan, Lynda https://orcid.org/0000-0001-9880-6560
Rosado, Victoria
Lemus, Nicholas
Jangra, Sonia
Rathnasinghe, Raveen
Schotsaert, Michael https://orcid.org/0000-0003-3156-3132
Martinez, Jose L.
Sano, Kaori
Mena, Ignacio https://orcid.org/0000-0001-5464-7086
Innis, Bruce L. https://orcid.org/0000-0002-1753-7248
Wirachwong, Ponthip
Thai, Duong Huu
Oliveira, Ricardo Das Neves
Scharf, Rami
Hjorth, Richard
Raghunandan, Rama
Krammer, Florian https://orcid.org/0000-0003-4121-776X
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
Palese, Peter https://orcid.org/0000-0002-0337-5823
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (HHSN272201400008C)
Bill and Melinda Gates Foundation (INV-021239)
- License Information
-
More Information
Article History
Received: 1 July 2021
Accepted: 6 October 2021
First Online: 27 October 2021
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications entitled “RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2 SPIKE PROTEIN AND USES THEREOF” which names P.P., F.K., AG-S., and W.S. as inventors. The AG-S laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Merck and Nanocomposix, and AG-S has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, and Pfizer. All other authors declared no competing interests.
